Tirza
Generic Name
Tirzepatide Injection
Manufacturer
Fictional Pharma Co. Ltd.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tirza 25 mg injection | ৳ 2,100.00 | N/A |
Description
Overview of the medicine
Tirza-25 mg injection contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is used to improve blood sugar control in adults with type 2 diabetes mellitus and for chronic weight management.
Uses & Indications
Dosage
Adults
The typical starting dose is 2.5 mg once weekly. The dose should be escalated in 2.5 mg increments every 4 weeks as tolerated to achieve glycemic and/or weight management goals. Tirza-25 mg is a higher therapeutic dose, intended for once-weekly subcutaneous administration.
Elderly
No specific dosage adjustment is required based on age alone. However, individual patient factors and renal function should be considered.
Renal_impairment
No dosage adjustment is needed for patients with mild, moderate, or severe renal impairment, or end-stage renal disease on dialysis.
How to Take
Administer Tirza-25 mg as a subcutaneous injection once weekly, any time of day, with or without meals. Inject into the abdomen, thigh, or upper arm. Rotate injection sites with each dose. Do not inject intravenously or intramuscularly.
Mechanism of Action
Tirzepatide activates both GIP and GLP-1 receptors. This dual agonism leads to increased insulin secretion, decreased glucagon secretion, delayed gastric emptying, and increased satiety, collectively resulting in reduced blood glucose levels and weight loss.
Pharmacokinetics
Onset
Glucose-lowering effects observed within days of initiation.
Excretion
Primary excretion via urine and feces as metabolites.
Half life
Approximately 5 days, allowing for once-weekly administration.
Absorption
Subcutaneous administration, peak plasma concentrations typically achieved 24-48 hours post-dose.
Metabolism
Undergoes extensive proteolytic cleavage, oxidation, and reduction, followed by conjugation.
Side Effects
Contraindications
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to tirzepatide or any of its excipients.
Drug Interactions
Oral contraceptives
Tirzepatide delays gastric emptying, which may reduce the absorption and efficacy of orally administered concomitant medications, particularly oral contraceptives. Patients should be advised to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and after each dose escalation.
Insulin secretagogues (e.g., sulfonylureas) or insulin
When Tirza-25 mg is initiated in patients receiving an insulin secretagogue or insulin, consider reducing the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.
Storage
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. If needed, the pen can be stored at room temperature (below 30°C/86°F) for up to 21 days.
Overdose
In the event of an overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. A period of observation and symptomatic treatment may be necessary due to the long half-life of tirzepatide.
Pregnancy & Lactation
Generally not recommended during pregnancy due to limited data and potential risks to the fetus. Should be used only if the potential benefit justifies the potential risk. It is unknown whether tirzepatide is excreted in human milk, thus caution should be exercised in nursing mothers.
Side Effects
Contraindications
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to tirzepatide or any of its excipients.
Drug Interactions
Oral contraceptives
Tirzepatide delays gastric emptying, which may reduce the absorption and efficacy of orally administered concomitant medications, particularly oral contraceptives. Patients should be advised to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and after each dose escalation.
Insulin secretagogues (e.g., sulfonylureas) or insulin
When Tirza-25 mg is initiated in patients receiving an insulin secretagogue or insulin, consider reducing the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.
Storage
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. If needed, the pen can be stored at room temperature (below 30°C/86°F) for up to 21 days.
Overdose
In the event of an overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. A period of observation and symptomatic treatment may be necessary due to the long half-life of tirzepatide.
Pregnancy & Lactation
Generally not recommended during pregnancy due to limited data and potential risks to the fetus. Should be used only if the potential benefit justifies the potential risk. It is unknown whether tirzepatide is excreted in human milk, thus caution should be exercised in nursing mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 months from manufacturing date when stored under recommended conditions.
Availability
Pharmacies, hospitals
Approval Status
Approved by FDA
Patent Status
Patented
Clinical Trials
Tirzepatide has been extensively studied in large-scale clinical trials (e.g., SURPASS and SYNERGY programs) demonstrating superior efficacy in glycemic control and significant weight reduction compared to other antidiabetic agents.
Lab Monitoring
- Monitor HbA1c and blood glucose levels periodically.
- Monitor for signs and symptoms of pancreatitis (e.g., persistent severe abdominal pain).
- Monitor for signs of gallbladder disease.
- Renal function (eGFR) should be assessed periodically, especially in patients with pre-existing renal impairment.
Doctor Notes
- Thoroughly educate patients on the proper subcutaneous injection technique and the importance of rotating injection sites.
- Counsel patients on the Black Box Warning regarding Medullary Thyroid Carcinoma (MTC) and to report any symptoms suggestive of thyroid tumors.
- Advise patients on symptoms of pancreatitis and gallbladder disease, emphasizing immediate medical attention if they occur.
Patient Guidelines
- Read the Instructions for Use carefully before administering Tirza-25 mg injection.
- Always rotate injection sites to prevent lipodystrophy.
- Report any severe abdominal pain, nausea, or vomiting immediately to your doctor.
- Monitor blood sugar levels as directed by your healthcare provider, especially if you are also taking insulin or sulfonylureas.
Missed Dose Advice
If a dose is missed and there are at least 4 days (96 hours) remaining before the next scheduled dose, administer Tirza as soon as possible. If less than 4 days remain, skip the missed dose and resume the regular once-weekly schedule. Do not take two doses within 3 days.
Driving Precautions
Tirza-25 mg may cause hypoglycemia, particularly when used with insulin or sulfonylureas, which could impair your ability to drive or operate machinery. Exercise caution, especially at the start of treatment or during dose escalation.
Lifestyle Advice
- Tirza-25 mg is an adjunct to diet and exercise. Maintain a balanced, reduced-calorie diet and engage in regular physical activity.
- Stay well-hydrated, especially when starting treatment or increasing the dose, to minimize gastrointestinal side effects.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Tirza Brand
Other medicines available under the same brand name
